Caribou Biosciences said Thursday that its CRISPR-edited T-cell therapy induced complete remissions in four of five patients with advanced B-cell lymphoma — the first clinical trial data to emerge from the biotech company co-founded by Nobel Prize winner Jennifer Doudna.
The study results are preliminary but establish Caribou’s presence among a group of drugmakers leveraging genome-editing technologies to engineer different types of immune cells into off-the-shelf, cancer-killing treatments.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
